Cochrane Review Group
Lung Cancer
21 systematic reviews in Lung Cancer ask 210 questions. 7.1% have no studies to answer them, 7.1% rest on very low certainty evidence and 53.3% reach moderate or high certainty.
Reviews
21
Questions
210
current versions
No studies
7.1%
Moderate or high
53.3%
No studies 15 · 7.1%Ungraded 2 · 1%Very low 15 · 7.1%Low 66 · 31.4%Moderate 50 · 23.8%High 62 · 29.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Epidermal growth factor vs best supportive care Health‐related quality of life · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | MD 7.9 | 1 study · 86 participants | Very low |
TG4010 added to chemotherapy vs chemotherapy alone Participants with at least one serious adverse event · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | RR 0.7 [0.23, 2.19] | 2 studies · 362 participants | Very low |
TG4010 added to chemotherapy vs chemotherapy alone Survival rates at 5 years · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | no estimate extracted | NR | No studies |
TG4010 added to chemotherapy vs chemotherapy alone Health‐related quality of life · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | no estimate extracted | NR | No studies |
Epidermal growth factor vs best supportive care Progression‐free survival · adults with advanced non‐small cell lung cancer (NSCLC) Therapeutic vaccines for advanced non‐small cell lung cancer (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Preoperative exercise training vs no exercise training Postoperative intercostal catheter duration · people scheduled to undergo lung resection for non‐small cell lung cancer Preoperative exercise training for people with non‐small cell lung cancer (2022) · Cochrane | no estimate extracted | 3 studies · 111 participants | Very low |
Summary of findings table ‐ Preoperative exercise training vs no exercise training Postintervention (preoperative) exercise capacity · people scheduled to undergo lung resection for non‐small cell lung cancer Preoperative exercise training for people with non‐small cell lung cancer (2022) · Cochrane | no estimate extracted | 6 studies · 474 participants | Very low |
Next‐generation ALK inhibitor vs crizotinib Health‐related quality of life: time to deterioration in composite endpoint (cough, dyspnoea, and chest pain) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer (2022) · Cochrane | HR 1.1 [0.72, 1.68] | 1 study · 303 participants | Very low |
Low‐dose computed tomography (LDCT) screening vs no LDCT screening  · healthy adults Impact of low‐dose computed tomography (LDCT) screening on lung cancer‐related mortality (2022) · Cochrane | no estimate extracted | NR | No studies |
Combined immune checkpoint inhibitors (ICIs) vs chemotherapy HRQoL · people with advanced non‐small cell lung cancer Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or… (2021) · Cochrane | no estimate extracted | NR | No studies |
Combined immune checkpoint inhibitors (ICIs) vs chemotherapy Progression‐free survival (PFS) · people with advanced non‐small cell lung cancer Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or… (2021) · Cochrane | no estimate extracted | NR | No studies |
Combined immune checkpoint inhibitors (ICIs) vs chemotherapy Overall response rate (OSR) · people with advanced non‐small cell lung cancer Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or… (2021) · Cochrane | no estimate extracted | NR | No studies |
Reviews 21
Therapeutic vaccines for advanced non‐small cell lung cancer
CochraneSoF table
12 questions
Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
CochraneSoF table
7 questions
Preoperative exercise training for people with non‐small cell lung cancer
CochraneSoF table
7 questions
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
CochraneSoF table
14 questions
Impact of low‐dose computed tomography (LDCT) screening on lung cancer‐related mortality
CochraneSoF table
7 questions
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
CochraneSoF table
8 questions
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent
CochraneSoF table
8 questions
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
CochraneSoF table
10 questions
Drugs for preventing lung cancer in healthy people
CochraneSoF table
46 questions
Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer
CochraneSoF table
6 questions
Exercise training undertaken by people within 12 months of lung resection for non‐small cell lung cancer
CochraneSoF table
7 questions
Non‐invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients
CochraneSoF table
5 questions
Exercise training for advanced lung cancer
CochraneSoF table
4 questions
Gefitinib for advanced non‐small cell lung cancer
CochraneSoF table
11 questions
Radical multimodality therapy for malignant pleural mesothelioma
CochraneSoF table
10 questions
Surgery for limited‐stage small‐cell lung cancer
CochraneSoF table
4 questions
Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer
CochraneSoF table
5 questions
Chemotherapy for advanced non‐small cell lung cancer in the elderly population
CochraneSoF table
16 questions
Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer
CochraneSoF table
6 questions
Chemotherapy versus best supportive care for extensive small cell lung cancer
CochraneSoF table
6 questions
Screening for lung cancer
CochraneSoF table
11 questions